IS2750B - Leiðarafesting - Google Patents
LeiðarafestingInfo
- Publication number
- IS2750B IS2750B IS6329A IS6329A IS2750B IS 2750 B IS2750 B IS 2750B IS 6329 A IS6329 A IS 6329A IS 6329 A IS6329 A IS 6329A IS 2750 B IS2750 B IS 2750B
- Authority
- IS
- Iceland
- Prior art keywords
- compounds
- conductor mount
- formula
- racemate
- tautomer
- Prior art date
Links
- 239000004020 conductor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16140799P | 1999-10-25 | 1999-10-25 | |
| SE9903838A SE9903838D0 (sv) | 1999-10-25 | 1999-10-25 | Novel compounds |
| US21281600P | 2000-06-21 | 2000-06-21 | |
| SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
| PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS6329A IS6329A (is) | 2002-04-02 |
| IS2750B true IS2750B (is) | 2011-08-15 |
Family
ID=27484521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6329A IS2750B (is) | 1999-10-25 | 2002-04-02 | Leiðarafesting |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1224172B1 (is) |
| JP (1) | JP3950337B2 (is) |
| KR (2) | KR100674160B1 (is) |
| AT (1) | ATE358668T1 (is) |
| AU (1) | AU775057B2 (is) |
| CA (1) | CA2386775C (is) |
| CZ (1) | CZ298534B6 (is) |
| DE (1) | DE60034240T2 (is) |
| DK (1) | DK1224172T3 (is) |
| EE (1) | EE200200207A (is) |
| ES (1) | ES2280258T3 (is) |
| HK (1) | HK1049830A1 (is) |
| HR (1) | HRP20020353A2 (is) |
| HU (1) | HU229072B1 (is) |
| IL (2) | IL148782A0 (is) |
| IS (1) | IS2750B (is) |
| NO (1) | NO323320B1 (is) |
| NZ (1) | NZ518296A (is) |
| SE (1) | SE0002320D0 (is) |
| UA (1) | UA73748C2 (is) |
| WO (1) | WO2001030758A1 (is) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| CN104788328B (zh) | 2004-06-24 | 2017-09-12 | 沃泰克斯药物股份有限公司 | Atp‑结合弹夹转运蛋白的调控剂 |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PT1937642E (pt) | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| KR20140091778A (ko) | 2006-06-12 | 2014-07-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
| EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| PL2234485T3 (pl) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stabilne preparaty lakwinimodu |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| KR20110048571A (ko) | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| SG10201504084QA (en) | 2009-03-20 | 2015-06-29 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| WO2012050500A1 (en) * | 2010-10-14 | 2012-04-19 | Lars Pettersson | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
| US8975279B2 (en) * | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| ES2631194T3 (es) * | 2014-09-23 | 2017-08-29 | Active Biotech Ab | Quinolincarboxamidas para usar en el tratamiento del mieloma múltiple |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016078921A1 (en) * | 2014-11-19 | 2016-05-26 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
| JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| BR112022010112A2 (pt) * | 2019-11-28 | 2022-09-06 | Bayer Ag | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica |
| MX2022010327A (es) | 2020-03-03 | 2022-11-09 | Active Biotech Ab | Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada. |
| AU2021275994A1 (en) * | 2020-05-21 | 2022-12-22 | Stemsynergy Therapeutics, Inc. | Notch inhibitors and uses thereof |
| JP2024503372A (ja) | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
| CA3218977A1 (en) | 2021-05-25 | 2022-12-01 | Hans Wannman | A plurality of tasquinimod particles and use thereof |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
| AR126963A1 (es) | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
| TWI838849B (zh) | 2021-09-13 | 2024-04-11 | 美商美國禮來大藥廠 | Ahr促效劑 |
| CA3241699A1 (en) * | 2021-12-20 | 2023-06-29 | The Johns Hopkins University | Compounds for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en not_active Ceased
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 EP EP00973329A patent/EP1224172B1/en not_active Expired - Lifetime
- 2000-10-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active Expired - Fee Related
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active Expired - Fee Related
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
-
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS2750B (is) | Leiðarafesting | |
| YU23202A (sh) | Lekovi za tretman malignih tumora | |
| BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| SE9904505D0 (sv) | Novel compounds | |
| PL367682A1 (en) | Dolastatin 10 derivatives | |
| SE0103836D0 (sv) | Novel compounds | |
| DK1200412T3 (da) | Antiproliferative imidazolforbindelser | |
| ATE277929T1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| ATE316083T1 (de) | Adamantanderivate | |
| GB0112348D0 (en) | Compounds | |
| EA200500376A1 (ru) | Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf) | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| NO20043016L (no) | 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav | |
| JO2390B1 (en) | Diphenylcarboxamides act as lipid-lowering agents | |
| SE0101038D0 (sv) | Novel compounds | |
| SE0003476D0 (sv) | Compounds | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
| AU2002357740A1 (en) | Pyrazolo-pyridine derivatives as antiherpes agents | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
| MXPA03008801A (es) | Aril oxima-piperazinas utiles como antagonistas de ccr5. | |
| AU2002248531A1 (en) | Pyrazolopyriadine derivatives | |
| SE9904128D0 (sv) | Novel compounds | |
| CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας |